Science in our DNA

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Leading scientific expertise

We combine a unique range of knowledge, skills and experience with a passion for following the science. Here are some examples of our key capabilities.

Partnering: a way of life

We work alongside scientists at leading institutions to better understand disease, identify potential new drugs and accelerate drug development. We’re also pioneers in creating a more open research environment.

Where science thrives

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries


Cambridge, United Kingdom

Our new facility in Cambridge will bring together our small molecule and biologics research and development activity. It will become our largest centre for oncology research and also house scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system.


Gothenburg, Sweden

Our vibrant science facility in Gothenburg is a world-leading centre for research and development in cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity. It also houses science teams responsible for all phases and aspects of small molecule drug discovery and development – from initial ideas through to new medicines.


Gaithersburg, Maryland, USA

Our Gaithersburg centre is headquarters to MedImmune and our primary location for biologics research and development in the US. It is also home to our Global Medicines Development function and Specialty Products Group. The modern, vibrant, scientific campus employs more than 3,000 experts in our field and is only a short drive from Washington, DC.

Two R&D organisations with one shared goal

Our two R&D organisations (BioPharmaceuticals and Oncology) are responsible for discovery through to late-stage development. This structure is designed to enable us to follow the science by accelerating promising early-stage assets and life-cycle management programmes, as well as providing new opportunities for combinations.

An exciting pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


projects in our pipeline


new molecular entities in our late-stage pipeline


new molecular entity approval in the last quarter